Key facts
- This page summarizes Milton C. Ault III's Form 4 filing for Alzamend Neuro, Inc. (ALZN).
- 1 reported transaction and 6 derivative rows are listed below.
- Accepted by SEC: 04 Aug 2026, 21:35.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
Each share of Series D Convertible Preferred Stock has a stated value of $1,050.00 and is convertible into shares of Common Stock at a conversion price equal to the greater of (i) $0.2668 and (ii) 80% of the lowest closing bid price of the Common Stock during the five (5) trading days immediately prior to the date of conversion into conversion shares, but not greater than $2.00 per share (the "Conversion Price"). The Conversion Price is subject to adjustment in the event of issuances of Common Stock at a price per share lower than the Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events.
Footnote F2
The Series D Convertible Preferred Stock has no expiration date.
Footnote F3
As of August 4, 2026, the Conversion Price was $1.016 per share, so each share of Series D Convertible Preferred Stock is convertible into approximately 1,033.5 shares of Common Stock.
Footnote F4
Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Capital Group, Inc. ("ACG"). ACG is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
Footnote F5
On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Ault to purchase 100,000 shares of Common Stock. Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders. Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable. The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026.
SEC remarks
Mr. Ault, the Executive Chairman of HSD, which wholly owns ACG, which in turn wholly owns Ault Lending, is a director of the Issuer. For purposes of Section 16 of the Exchange Act, each of HSD, ACG and Ault Lending may be deemed a director by deputization by virtue of their respective representation on the Board of Directors of the Issuer.